Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 14000 shares changing hands. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Stock Performance
The company has a debt-to-equity ratio of 138.88, a quick ratio of 0.46 and a current ratio of 0.07. The stock has a 50 day moving average of C$0.01 and a 200 day moving average of C$0.01. The stock has a market capitalization of C$663,150.00, a P/E ratio of -0.50 and a beta of -0.02.
Aequus Pharmaceuticals Company Profile
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Further Reading
- Five stocks we like better than Aequus Pharmaceuticals
- What is diluted earnings per share (Diluted EPS)?
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- Options Trading – Understanding Strike Price
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
